What You Need to Know About Medivation Inc.'s Results
Medivation (MDVN) and Astellas (ALPMY) saw U.S. sales growth slow this quarter, but growth overseas took off. Here's what could be in store for these stocks through the rest of the year.
Why Medivation Inc. Shares Roared Higher
Medivation shares surge after it reports its first-quarter earnings results after the closing bell last night. Can shares head even higher?
Medivation's Q1 Loss Shrinks by 50% as Xtandi Revenue Soars
Medivation and Astellas Pharma's Xtandi sales take off both inside and outside the U.S., helping Medivation halve its quarterly loss from the year-ago quarter.
Tuesday’s Top Health Care Stories: Bayer, Merck, Medivation, and AstraZeneca
Bayer, Merck, Medivation, and AstraZeneca could all loom large in health care headlines this Tuesday morning. Here’s why.
Is There Value In Cytokinetics Following Its 60% Drop?
Cytokinetics (CYTK) mid stage trial for its promising ALS drug failed, shifting attention to collaborations with Amgen (AMGN) and Astellas (ALPMY).
3 Drugs Johnson & Johnson’s Investors Better Know About
Johnson & Johnson's (JNJ) sales are being driven by a handful of fast-growing drugs. Here are three investors should be watching because of competitive threats from AstraZeneca (AZN), Pfizer (PFE), and Medivation (MDVN).
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Growth for Johnson & Johnson's (JNJ) blockbuster Zytiga is being weighed down by Medivation (MDVN) and Astellas (ALPMY) Xtandi.
Why I Bought Exelixis
The author shares his opinion why the recent drop in Exelixis is an incredible buying opportunity.
Medivation, Inc: Fast Growing Drugs That May Become Blockbusters
Medivation (MDVN) may see sales of its prostate cancer drug Xtandi hit a blockbuster run rate this year.
Was Medivation's Quarter a Disaster?
Medivation (MDVN) shares sank more than 10% on news of slowing sales growth for its prostate cancer drug Xtandi; however, an FDA decision and potential milestones may support the company into year end.